Blossom Innovations Advances Its Latest Medical Technology Platform for Dermatology

BOSTON–(BUSINESS WIRE)–Blossom
Innovations LLC, a medical technology company specializing in
dermatology, announces its next success, a cold-based medical device
technology to address pigmentation issues related to aging, sun damage,
and genetics.

The device will be commercialized by R2
Dermatology, a Blossom Innovations company. Founded in 2014 by
Pansend Life Sciences, a subsidiary of HC2 Holdings and Blossom
Innovations, R2 Dermatology recently entered into an agreement granting
exclusive distribution rights to Huadong
Medicine Company Limited for R2’s products in the Asia-Pacific.
Huadong is leading the latest round of equity investment in R2
Dermatology.

“As innovators, it is exceptionally rewarding when one of our
technologies progresses towards global commercialization,” said Irina
Erenburg, Ph.D., co-founder, president, & CEO of Blossom
Innovations. “We are thrilled to have R2 Dermatology work with Huadong
Medicine to help us enter the largest market for skin lightening medical
devices.”

Blossom Innovations addresses challenging clinical conditions primarily
in the area of dermatology through the combined effort of their founders
– an innovation team of the most respected researchers and clinicians in
dermatology. From white board inception to clinical feasibility, Blossom
invents revolutionary medical device technology platforms that are then
transferred for product development and commercialization.

This latest device was created by scientists R. Rox Anderson, M.D.,
director of the Wellman Center at Massachusetts General Hospital, a
teaching affiliate of Harvard Medical School – Department of
Dermatology; Dieter Manstein, M.D., Ph.D., Department of Dermatology at
Massachusetts General Hospital; and Henry H.L. Chan, M.D., Ph.D.,
Department of Medicine, The University of Hong Kong and the visiting
scientist of the Wellman Center, Massachusetts General Hospital.

“Advances in the understanding of fundamental biology and skin response
to controlled, precision cooling have allowed us to create a technology
platform that modulates cellular response without harming underlying
tissue,” added R.
Rox Anderson, M.D., co-founder of Blossom Innovations.

“The new cold-based medical device technology platform provides a safe
and comfortable patient experience, offers predictable outcomes, and
requires no patient downtime,” said Henry H.L. Chan, M.D., Ph.D.,
co-founder and chairman of Blossom’s board. “We look forward to future
regulatory submission in Asia, most importantly in China, where there is
a significant unmet clinical need.”

About Blossom Innovations
Blossom Innovations, whose
founders and leadership team are world-renowned in the field of
dermatology and aesthetic medicine, invents breakthrough medical devices
and drug-device combination products. Our unique R&D approach synergizes
expertise in biology, physics, and medicine to impact patient care using
individualized precision therapy and novel treatment platforms designed
to address major unmet clinical dermatologic conditions. For more
information: blossominnovations.com.

About R2 Dermatology
R2 Dermatology is a Blossom Innovations
company, located in San Ramon, California. Founded in late 2014, R2
Dermatology is developing medical devices for the treatment of aesthetic
and medical skin conditions, including a skin lightening and skin tone
evening product utilizing “cold technology”. R2 Dermatology has received
market clearance from the U.S. Food and Drug Administration for its
second generation device, the R2 Dermal Cooling System, a cryosurgical
instrument intended for use in dermatologic procedures for the removal
of benign lesions of the skin, based on exclusive licensing rights to a
novel technology invented by Blossom Innovations and Massachusetts
General Hospital, teaching affiliate of Harvard Medical School. Learn
more about R2 Dermatology at www.r2derm.com.

Contacts

Jenifer Perry
Blossom Innovations
info@blossominnovations.com